Abstract: The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.

Abstract: A task processing method includes: acquiring target data and target algorithm required by a target task to be executed; acquiring from a network topology at least one first-type node capable of providing the target data and at least one second-type node capable of executing the target algorithm; selecting, from the at least one first-type node, a node that provides one set of target data as a first target node, and selecting, from the at least one second-type node, a node that provides one set of target algorithm as a second target node; and controlling the second target node to process the target data in the first target node by using the target algorithm.

Abstract: The embodiments of the disclosure provide a computer system, comprising a plurality of computing devices, each computing device comprising a storage unit and at least one computing unit which are connected in parallel, the plurality of computing devices being divided into a plurality of nodes, and the plurality of nodes forming a network topology; a communication device comprising an autonomous domain building module and a first communication module, the first communication module being configured for connecting the plurality of computing devices in a communication manner; and a task processing device comprising an addressing module and a task processing module. Therefore, the solution of the present disclosure meets the explosive demand of massive data and large amount computing power caused by artificial intelligence and blockchain to a certain extent.

Abstract: The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.

Abstract: The embodiments of the disclosure provide a computer system, comprising a plurality of computing devices, each computing device comprising a storage unit and at least one computing unit which are connected in parallel, the plurality of computing devices being divided into a plurality of nodes, and the plurality of nodes forming a network topology; a communication device comprising an autonomous domain building module and a first communication module, the first communication module being configured for connecting the plurality of computing devices in a communication manner; and a task processing device comprising an addressing module and a task processing module. Therefore, the solution of the present disclosure meets the explosive demand of massive data and large amount computing power caused by artificial intelligence and blockchain to a certain extent.

Abstract: Embodiments of the present invention provide a task processing method and apparatus, and an electronic device. The method comprises: acquiring target data and target algorithm required by a target task to be executed; acquiring from a network topology at least one first-type node capable of providing the target data and at least one second-type node capable of executing the target algorithm; selecting, from the at least one first-type node, a node that provides one set of target data as a first target node, and selecting, from the at least one second-type node, a node that provides one set of target algorithm as a second target node; and controlling the second target node to process the target data in the first target node by using the target algorithm.

Abstract: The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.

Abstract: A method, device and system for controlling a fuel cell and a rail vehicle are provided. The method includes: an operating power of a target object is detected, wherein the target object is powered by at least two fuel cells (S102); when it is detected that the operating power of the target object is lower than a predetermined power, at least one fuel cell is turned off or a cell component in any one or more fuel cells is turned off according to a gas conversion range corresponding to the fuel cell (S104), wherein the gas conversion range is an output power range value, of the fuel cell, corresponding to a preset range value of a hydrogen conversion rate of the fuel cell.

Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic M retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9.

Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.

Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5, C6, C7, C8, C9, or C5b-9.

Abstract: The present invention discloses an intelligent traffic safety system based on comprehensive state detection and decision method thereof. The intelligent traffic safety system includes a person condition detection unit, a vehicle condition detection unit, a road condition detection unit, an intelligent decision unit, a driver warning unit, a current vehicle mandatory processing unit, a barrier warning unit, a pursuer warning unit and an after-crash warning unit.

Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9.

Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.

Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.

Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.

Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.

Abstract: The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (“NEAT”) receptor, and related compositions and methods.

Abstract: Isolated receptors for CTLA-8, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to inhibit an immune response.